Universitätsklinikum Bonn

Klinik für Psychiatrie und Psychotherapie

Prof. Alexandra Philipsen

• All clinical centers
• Rijksuniversiteit Groningen

• Conduct the 24-week randomized, patient- and rater-blind, two-arm, parallel-group controlled trial of pharmacogenetics-informed pharmacotherapy in 9 centers across 7 European countries and the US. This will be done in n=2500 patients starting or alternating psychopharmacotherapy for mood disorders (group 1, n=1250), anxiety disorders (group 2, n=750), and psychotic disorders (group 3, n=500)Big data will be obtained from Finnish and UK genetic databases to assess pharmacogenetic genotype and clinical outcomes in patients with mood-, anxiety or psychotic disorders to investigate real-world, large-scale and long-term perspectives on outcomes of specific disease – medication stratified by CYP2C19 and CYP2D6 genotype.